| Day 1: March 27, 2021(Saturday) | |||
| 09:00-20:00 | Registration | ||
| 09:00-20:00 | Booth Set up | ||
| Day 2: March 28, 2021 (Sunday) | |||
| 09:00-09:15 | Opening Ceremony | ||
| 09:15-11:00 | Keynote Forum | ||
| 11:00-12:00 | Entrepreneurship Summit of Biopharma | ||
| 13:30-17:30 | Section 1: Cellular Immunotherapy | Section 3: Biopharma R&D Innovation | Section 5: Stem Cell Research & Therapy |
| Advances and Future Trends of Cellular Immunotherapy Challenges in Cancer Immunotherapy New Targets NK, LAK, DC, CIK, CTL, TIL, TCR-T, CAR-T T-Cell Immunotherapy for Solid Tumors Supervision and Approval Cell Therapy Manufacturing |
Antibody Drug R&D Investment Trends PD-1/PD-L1 Bispecific Antibody Recombinant Protein Drugs ADC Drug Development Challenges COVID-19 Antibody Treatment Nanobodies Therapeutic Vaccines |
Advances and Challenges in Stem Cell Research and Transformation Policy and Regulation Development of Stem Cell Therapy products Clinical Research The Pharmacy of Stem Cells Registration declaration iPS Technology Organs to Assist of New Drugs Cell Banking and Storage |
|
| Day 3: March 29, 2021 (Monday) | |||
| 09:00-12:00 | Section 2: Gene Therapy & Oncolytic Virus | Section 4: Bioprocess & Manufacturing | Section 6: RNA Targeted Drug R&D |
| Advances in the Gene Therapy Products Crispr/cas9 Accuracy and Security of Editing Techniques Oncolytic Virus Adeno-Associated Viral, Adenovirus, Lentivira Clinical Research |
Cell Culture and Upstream Processing Application of Disposable Technologies for Upstream Application of QbD for the Development of Biopharmaceuticals Separation and Purification Technology Continuous Processing in Downstream Operations Process Optimization and Control Quality Risk Management Biopharmaceutical Plant Design |
RNA Structure, Sunction & Role in Disease Antisense Oligonucleotides (ASO) Drugs R&D Small interfering RNA (siRNA) Drugs R&D Micro RNA (miRNA) Drugs R&D RNA-Based Vaccines R&D Delivery Systems for RNA Drug Development Manufacturing RNA-Based Biopharmaceuticals |
|